Skip to main content
SpringerLink
Log in
Book cover

Clinical Ophthalmic Oncology pp 249–261Cite as

Prognostication in Choroidal Melanoma

  • Chapter
  • First Online:

  • 821 Accesses

Abstract

Without timely treatment, uveal melanomas (UM) make the affected eye blind and painful. Despite successful ocular treatment, about 50 % of UM patients develop metastatic disease, which usually involves the liver. Treatment of metastases only rarely prolongs life. Most patients die within a year of onset of symptomatic metastases. It is hoped that such metastatic disease may be delayed or prevented by systemic adjuvant therapy administered soon after treatment of the primary ocular tumor. This approach would require identification of high-risk patients, that is, individuals who are likely to have micrometastases by the time their primary ocular tumor is detected and treated.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Damato B. Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. Eye (Lond). 2012;26(9):1157–72.

    Article  CAS  Google Scholar 

  2. Frenkel S, Nir I, Hendler K, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol. 2009;93(8):1042–6.

    Article  CAS  PubMed  Google Scholar 

  3. Mariani P, Servois V, Piperno-Neumann S. Therapeutic options in metastatic uveal melanoma. Dev Ophthalmol. 2011;49:166–81.

    Article  PubMed  Google Scholar 

  4. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651–9.

    Article  PubMed  Google Scholar 

  5. Whitehead J, Tishkovskaya S, O'Connor J, Damato B. Devising two-stage and multistage phase II studies on systemic adjuvant therapy for uveal melanoma. Invest Ophthalmol Vis Sci. 2012;53(8):4986–9.

    Article  CAS  PubMed  Google Scholar 

  6. Damato B, Duke C, Coupland SE, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology. 2007;114(10):1925–31.

    Article  PubMed  Google Scholar 

  7. Damato BE, Coupland SE. Differences in uveal melanomas between men and women from the British Isles. Eye (Lond). 2011;26(2):292–9.

    Article  Google Scholar 

  8. Damato B, Eleuteri A, Taktak AF, Coupland SE. Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res. 2011;30(5):285–95.

    Article  PubMed  Google Scholar 

  9. Khan S, Finger PT, Yu GP, et al. Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol. 2011;130(1):57–64.

    Article  PubMed  Google Scholar 

  10. Kivela T, Kujala E. Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond. Eye (Lond). 2013;27(2):243–52.

    Article  CAS  Google Scholar 

  11. Eleuteri A, Damato B, Coupland SE, Taktak A. Enhancing survival prognostication in patients with choroidal melanoma by integrating pathologic, clinical and genetic predictors of metastasis. Int J Biomed Eng Technol. 2012;8:18–35.

    Article  Google Scholar 

  12. Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst. 1990;82(22):1765–9.

    Article  CAS  PubMed  Google Scholar 

  13. Sisley K, Cottam DW, Rennie IG, et al. Non-random abnormalities of chromosomes 3, 6, and 8 associated with posterior uveal melanoma. Genes Chromosomes Cancer. 1992;5(3):197–200.

    Article  CAS  PubMed  Google Scholar 

  14. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347(9010):1222–5.

    Article  CAS  PubMed  Google Scholar 

  15. White VA, Chambers JD, Courtright PD, Chang WY, Horsman DE. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer. 1998;83(2):354–9.

    Article  CAS  PubMed  Google Scholar 

  16. Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res. 2010;16(24):6083–92.

    Article  CAS  PubMed  Google Scholar 

  17. Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE. Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci. 2009;50(7):3048–55.

    Article  PubMed  Google Scholar 

  18. Coupland SE, Kalirai H, Baudo M, Maye U, Zeschnigk M, Damato B. Quality assessment of multiplex ligation-dependent probe amplification (MLPA) in uveal melanoma by comparison with array comparative genomic hybridization (aCGH) and microsatellite analysis (MSA). ARVO Abstract. 2012.

    Google Scholar 

  19. Hömig-Hölzel C, Savola S. Multiplex ligation-dependent probe amplification (MLPA) in tumor diagnostics and prognostics. Diagn Mol Pathol. 2012;21(4):189–206.

    Article  PubMed  Google Scholar 

  20. Schwab CJ, Jones LR, Morrison H, et al. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2010;49(12):1104–13.

    Article  CAS  PubMed  Google Scholar 

  21. Sisley K, Nichols C, Parsons MA, Farr R, Rees RC, Rennie IG. Clinical applications of chromosome analysis, from fine needle aspiration biopsies, of posterior uveal melanomas. Eye (Lond). 1998;12(Pt 2):203–7.

    Article  Google Scholar 

  22. Bonaldi L, Midena E, Filippi B, et al. FISH analysis of chromosomes 3 and 6 on fine needle aspiration biopsy samples identifies distinct subgroups of uveal melanomas. J Cancer Res Clin Oncol. 2008;134(10):1123–7.

    Article  CAS  PubMed  Google Scholar 

  23. Midena E, Bonaldi L, Parrozzani R, Radin PP, Boccassini B, Vujosevic S. In vivo monosomy 3 detection of posterior uveal melanoma: 3-year follow-up. Graefes Arch Clin Exp Ophthalmol. 2008;246(4):609–14.

    Article  PubMed  Google Scholar 

  24. Singh AD, Aronow ME, Sun Y, et al. Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array. Invest Ophthalmol Vis Sci. 2012;53(7):3331–9.

    Article  CAS  PubMed  Google Scholar 

  25. Gordon KB, Thompson CT, Char DH, et al. Comparative genomic hybridization in the detection of DNA copy number abnormalities in uveal melanoma. Cancer Res. 1994;54(17):4764–8.

    CAS  PubMed  Google Scholar 

  26. Speicher MR, Prescher G, du Manoir S, et al. Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization. Cancer Res. 1994;54(14):3817–23.

    CAS  PubMed  Google Scholar 

  27. Ghazvini S, Char DH, Kroll S, Waldman FM, Pinkel D. Comparative genomic hybridization analysis of archival formalin-fixed paraffin-embedded uveal melanomas. Cancer Genet Cytogenet. 1996;90(2):95–101.

    Article  CAS  PubMed  Google Scholar 

  28. Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42(2):313–7.

    CAS  PubMed  Google Scholar 

  29. Hughes S, Damato BE, Giddings I, Hiscott PS, Humphreys J, Houlston RS. Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3. Br J Cancer. 2005;93(10):1191–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Kilic E, van Gils W, Lodder E, et al. Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis Sci. 2006;47(9):3703–7.

    Article  PubMed  Google Scholar 

  31. Ehlers JP, Worley L, Onken MD, Harbour JW. Integrative genomic analysis of aneuploidy in uveal melanoma. Clin Cancer Res. 2008;14(1):115–22.

    CAS  PubMed  Google Scholar 

  32. Petrausch U, Martus P, Tonnies H, et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond). 2008;22(8):997–1007.

    Article  CAS  Google Scholar 

  33. Vaarwater J, van den Bosch T, Mensink HW, et al. Multiplex ligation-dependent probe amplification equals fluorescence in-situ hybridization for the identification of patients at risk for metastatic disease in uveal melanoma. Melanoma Res. 2011;22(1):30–7.

    Google Scholar 

  34. Shields CL, Ganguly A, Bianciotto CG, Turaka K, Tavallali A, Shields JA. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology. 2010;118(2):396–401.

    Article  Google Scholar 

  35. Thomas S, Putter C, Weber S, Bornfeld N, Lohmann DR, Zeschnigk M. Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study. Br J Cancer. 2012;106(6):1171–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Onken MD, Worley LA, Person E, Char DH, Bowcock AM, Harbour JW. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res. 2007;13(10):2923–7.

    Article  CAS  PubMed  Google Scholar 

  37. Trolet J, Hupe P, Huon I, et al. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci. 2009;50(6):2572–80.

    Article  PubMed  Google Scholar 

  38. McCannel TA, Burgess BL, Nelson SF, Eskin A, Straatsma BR. Genomic identification of significant targets in ciliochoroidal melanoma. Invest Ophthalmol Vis Sci. 2010;52(6):3018–22.

    Article  Google Scholar 

  39. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010;12(4):461–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596–603.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Taktak AF, Fisher AC, Damato BE. Modelling survival after treatment of intraocular melanoma using artificial neural networks and Bayes theorem. Phys Med Biol. 2004;49(1):87–98.

    PubMed  Google Scholar 

  43. Eleuteri A, Aung MS, Taktak AF, Damato B, Lisboa PJ. Continuous and discrete time survival analysis: neural network approaches. Conf Proc IEEE Eng Med Biol Soc. 2007;2007:5420–3.

    CAS  PubMed  Google Scholar 

  44. Damato B, Eleuteri A, Fisher AC, Coupland SE, Taktak AF. Artificial neural networks estimating survival probability after treatment of choroidal melanoma. Ophthalmology. 2008;115(9):1598–607.

    Article  PubMed  Google Scholar 

  45. Harrell F. Parametric survival models. In: Regression modeling strategies. Heidelberg: Springer; 2001. p. 413–41.

    Chapter  Google Scholar 

  46. Cook SA, Damato B, Marshall E, Salmon P. Psychological aspects of cytogenetic testing of uveal melanoma: preliminary findings and directions for future research. Eye (Lond). 2009;23(3):581–5.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, 6th Floor Duncan Building, Daulby Street, Liverpool, L69 3GA, UK

    Sarah E. Coupland MBBS, PhD & Helen Kalirai

  2. Department of Clinical Engineering, Royal Liverpool University Hospital, Liverpool, UK

    Azzam Taktak & Antonio Eleuteri

  3. Ocular Oncology Service, Departments of Ophthalmology and Ocular Oncology, University of California San Francisco, 10 Koret Way, San Francisco, CA, 94143, USA

    Bertil Damato MD, PhD, FRCOphth

Authors
  1. Sarah E. Coupland MBBS, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Azzam Taktak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio Eleuteri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Helen Kalirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bertil Damato MD, PhD, FRCOphth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah E. Coupland MBBS, PhD .

Editor information

Editors and Affiliations

  1. Ocular Oncology Service, Departments of Ophthalmology and Radiation Oncology, University of California, San Francisco, San Francisco, California, USA

    Bertil Damato

  2. Dept. of Ophthalmic Oncology, Cole Eye Institute Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Arun D. Singh

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Coupland, S.E., Taktak, A., Eleuteri, A., Kalirai, H., Damato, B. (2014). Prognostication in Choroidal Melanoma. In: Damato, B., Singh, A. (eds) Clinical Ophthalmic Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54255-8_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54255-8_20

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54254-1

  • Online ISBN: 978-3-642-54255-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation